ERIS - Eesti teadus- ja arendustegevuse infosüsteem

Elulookirjeldus (CV)
1.	Eesnimi	Kersti
2.	Perekonnanimi	Oselin
3.	Töökoht	TÜ farmakoloogia instituut
4.	Ametikoht	teadur
5.	Sünniaeg	26.07.1973 (päev.kuu.aasta)
6.	Haridus	1998 - 2003 TÜ arstiteaduskond kliiniline farmakoloogia doktorantuur 1997 - 1998 SA TÜ Kliinikum internatuur 1991 - 1997 TÜ arstiteaduskond ravi eriala
7.	Teenistuskäik	2004 - TÜ farmakoloogia instituut, teadur 2003 - 2004 AS EGeen farmakogeneetiliste uuringute projektijuht 2002 - 2003 TÜ farmakoloogia instituut assistent 2000 - 2002 Humboldti Ülikool Charité Kliinik kliinilis farmakoloogia instituut teadur 1999 - 2000 TÜ farmakoloogia instituut assistent
8.	Teaduskraad	meditsiinidoktor
9.	Teaduskraadi välja andnud asutus, aasta	Tartu Ülikool, 2003
10.	Tunnustused	2003 FEBS Youth Travel Fund Scholarship 2004 Cambridge Colleges Hospitality Scheme
11.	Teadusorganisatsiooniline ja –administratiivne tegevus	Eesti Farmakoloogia Selts, juhatuse liige Eesti Biokeemia Selts, liige
12.	Juhendamisel kaitstud väitekirjad
13.	Teadustöö põhisuunad	kliiniline farmakokineetika, rakumembraani transporterid, biotransformatsiooni ensüümid.
14.	Jooksvad grandid	Uus grant taotluses
15.	Teaduspublikatsioonid	Kalev I, Oselin K, Parlist P, Zilmer M, Rajasalu T, Podar T, Mikelsaar AV. CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications 2003;17:387-91. Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam & Clin Pharmacol 2003;17:463-469. Oselin K, Mrozikiewicz PM, Gaikovitch E, Pähkla R, Roots I. Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 2003;59:347-350. Oselin K, Mrozikiewicz PM, Pähkla R, Roots I. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 2003;71:119-123. Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolbergs D, Pähkla R, Roots I. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest 2003;33:261-267. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I. MDR1 genotype do not discriminate between absorptive pharmacokinetic parameters of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54:610-616.

viimati muudetud: 09.10.2005

Curriculum Vitae (CV)
1.	First Name	Kersti
2.	Surname	Oselin
3.	Institution	Institute of Pharmacology, University of Tartu
4.	Position	Research Fellow
5.	Date of birth	26.07.1973 (day.month.year)
6.	Education	1998 - 2003 PhD-studies in clinical pharmacology, University of Tartu 1997 - 1998 Internship, Tartu University Clinics 1991 - 1997 Medical Faculty, University of Tartu.
7.	Research and professional experience	2004 - Institute of Pharmacolgy, University of Tartu, researcher 2003 - 2004 EGeen International Corporation, project manager of pharmacogenetic studies 2002 - 2003 Institute of Pharmacolgy, University of Tartu, assistent 2000 - 2002 University of Humboldt, Charité Clinics, Institute of Clinical Pharmacology, researcher 1999 - 2000 Institute of Pharmacolgy, University of Tartu, assistent
8.	Academic degree	Ph.D.
9.	Dates and sites of earning the degrees	University of Tartu, 1998
10.	Honours/awards	2003 FEBS Youth Travel Fund Scholarship 2004 Cambridge Colleges Hospitality Scheme
11.	Research-administrative experience	Estonian Society of Farmocology, member of board Estonian Society of Biochemistry, member
12.	Supervised dissertations
13.	Current research program	Clinical pharmacokinetics; cell membrane transporters; enzymes of biotransformation
14.	Current grant funding
15.	List of most important publications	Kalev I, Oselin K, Parlist P, Zilmer M, Rajasalu T, Podar T, Mikelsaar AV. CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications 2003;17:387-91. Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam & Clin Pharmacol 2003;17:463-469. Oselin K, Mrozikiewicz PM, Gaikovitch E, Pähkla R, Roots I. Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 2003;59:347-350. Oselin K, Mrozikiewicz PM, Pähkla R, Roots I. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 2003;71:119-123. Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolbergs D, Pähkla R, Roots I. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest 2003;33:261-267. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I. MDR1 genotype do not discriminate between absorptive pharmacokinetic parameters of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54:610-616.

last updated: 09.10.2005